Companies Geron Corp
Geron (GERN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Geron Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $10,221,755FY2025
CEO total pay was $10,221,755 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $321,538 · bonus $0 · stock awards $0 · option awards $9,695,400
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Harout Semerjian | $321,538 | $0 | $0 | $9,695,400 | $203,000 | $0 | $1,817 | $10,221,755 |
| President and Chief Executive Officer | ||||||||
| John Scarlett | 309,781 | 0 | 1,078,300 | 4,308,104 | 0 | 0 | 1,726,569 | 7,422,754 |
| Former Chairman of the Board, President and Chief Executive Officer | ||||||||
| Andrew Grethlein | 563,276 | 0 | 368,200 | 1,474,253 | 0 | 0 | 910,715 | 3,316,444 |
| Former Executive Vice President, Chief Operating Officer | ||||||||
| Ahmed ElNawawi | 107,692 | 200,000 | 0 | 2,573,400 | 0 | 0 | 242 | 2,881,334 |
| Executive Vice President, Chief Commercial Officer | ||||||||
| James Ziegler | 470,028 | 0 | 234,070 | 927,549 | 0 | 0 | 761,062 | 2,392,709 |
| Former Executive Vice President, Chief Commercial Officer | ||||||||
| Michelle Robertson | 559,800 | 0 | 289,300 | 1,150,230 | 239,300 | 0 | 11,452 | 2,250,082 |
| Executive Vice President, Chief Financial Officer, Treasurer and Interim Secretary | ||||||||
| Joseph Eid | 650,000 | 0 | 0 | 0 | 339,600 | 0 | 11,452 | 1,001,052 |
| Executive Vice President, Research and Development, Chief Medical Officer | ||||||||
| Dawn Bir | 318,190 | 0 | 0 | 163,674 | 0 | 0 | 40,258 | 522,122 |
| Former Interim President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Harout Semerjian | $10,221,755 | — | — | — |
| John Scarlett | 7,422,754 | 6,125,238 | 4,924,092 | ↑ +1,297,516 |
| Andrew Grethlein | 3,316,444 | 2,813,956 | 2,415,091 | ↑ +502,488 |
| Ahmed ElNawawi | 2,881,334 | — | — | — |
| James Ziegler | 2,392,709 | — | — | — |
| Michelle Robertson | 2,250,082 | 2,147,216 | 2,469,659 | ↑ +102,866 |
| Joseph Eid | 1,001,052 | — | — | — |
| Dawn Bir | 522,122 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We believe that the leadership of our current executive management team is critical as we execute on our U.S. RYTELO commercial strategy and pursue paths to make RYTELO available to eligible LR-MDS patients outside of the U.S., including in the EU. Our industry is highly scientific, clinical, regulated and dynamic, which requires an executive management team that is exceptionally educated, dedicated and experienced. We also believe that the work of our executive officers, including our continuing Named Executive Officers, toward accomplishing our corporate goals is highly collaborative and team-oriented, and we strive to ensure that the total compensation levels for our executives are competitive with those of other companies in our industry that compete with us for executive talent.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Scarlett | RSU | 2025-02-18 | — | — | 410,000 | — | $1,078,300 |
| Harout Semerjian | OPTION | 2025-08-07 | — | — | 11,000,000 | — | 9,695,400 |
| Andrew Grethlein | RSU | 2025-02-18 | — | — | 140,000 | — | 368,200 |
| James Ziegler | RSU | 2025-02-18 | — | — | 89,000 | — | 234,070 |
| Michelle Robertson | RSU | 2025-02-18 | — | — | 110,000 | — | 289,300 |
| Ahmed ElNawawi | OPTION | 2025-10-20 | — | — | 3,000,000 | — | 2,573,400 |
| Andrew Grethlein | OPTION | 2025-10-16 | — | — | 78,125 | — | 3,150 |
| Dawn Bir | OPTION | 2025-05-21 | — | — | 180,000 | — | 163,674 |
| James Ziegler | OPTION | 2025-02-18 | — | — | 529,000 | — | 927,549 |
| Andrew Grethlein | OPTION | 2025-02-18 | — | — | 839,000 | — | 1,471,103 |
| Michelle Robertson | OPTION | 2025-02-18 | — | — | 656,000 | — | 1,150,230 |
| John Scarlett | OPTION | 2025-02-18 | — | — | 2,457,000 | — | 4,308,104 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Scarlett | $1,078,300 | $0 | $4,308,104 | 0.0% |
| Harout Semerjian | 0 | 0 | 9,695,400 | 0.0% |
| Andrew Grethlein | 368,200 | 0 | 1,474,253 | 0.0% |
| James Ziegler | 234,070 | 0 | 927,549 | 0.0% |
| Michelle Robertson | 289,300 | 0 | 1,150,230 | 0.0% |
| Ahmed ElNawawi | 0 | 0 | 2,573,400 | 0.0% |
| Dawn Bir | 0 | 0 | 163,674 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dawn Bir | Option | 180,000 | 1.34 | $280,800 |
| Andrew Grethlein | Option | 529,000 | 2.63 | — |
| John Scarlett | Option | 966,000 | 2 | — |
| Joseph Eid | Option | 2,220,000 | 1.8 | — |
| Joseph Eid | Option | 3,000,000 | 1.27 | — |
| Michelle Robertson | Option | 3,166,000 | 2.18 | — |
| Andrew Grethlein | Option | 3,483,000 | 2.24 | — |
| Andrew Grethlein | Option | 5,070,844 | 1.84 | — |
| Andrew Grethlein | Option | 9,352,000 | 1.99 | — |
| John Scarlett | Option | 13,039,750 | 1.84 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Elizabeth G. O'FarrellIndependent | $118,736 | $0 | $163,674 | $0 | $0 | $282,410 |
| Susan M. MolineauxIndependent · Audit (Chair) · Compensation | 70,000 | 0 | 163,674 | 0 | 0 | 233,674 |
| V. Bryan LawlisIndependent · Compensation · Not standing for re-election | 69,558 | 0 | 163,674 | 0 | 0 | 233,232 |
| John F. McDonaldIndependent · Audit | 68,125 | 0 | 163,674 | 0 | 0 | 231,799 |
| Robert J. SpiegelIndependent · Audit · Compensation | 62,500 | 0 | 163,674 | 0 | 0 | 226,174 |
| Gaurav AggarwalIndependent | 55,938 | 0 | 163,674 | 0 | 0 | 219,612 |
| Dawn C. BirIndependent · Compensation · Nominating/Governance (Chair) | 0 | 0 | 0 | 0 | 0 | 0 |
| Patricia S. AndrewsIndependent · Audit · Nominating/Governance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Harout SemerjianEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Constantine ChinoporosIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| John A. ScarlettEmployee director · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $163,674 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $444,857 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $444,857 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Geron as a peer
Companies that benchmark against GERN
8 companies name GERN as a compensation peer
The list of companies that name GERN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Geron Corp names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | $918,531 | $12,297,850 | $4,537,146 | $1,438,814 | $19,206,341 |
| 2 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 3 | Geron Corp | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 4 | Revance Therapeutics, Inc. | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 5 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 6 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 7 | Coherus Oncology, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 8 | Seres Therapeutics, Inc. | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Geron Corp | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Coherus Oncology, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Madrigal Pharmaceuticals | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Revance Therapeutics, Inc. | 96.8% | PSU 100 | No | FW Cook |
| Seres Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 372,129,132 | 19,673,460 | 1,400,387 | 94.64% | Passed |
| 2025 | 2025-05-21 | 361,788,628 | 33,922,666 | 1,009,544 | 91.43% | Passed |
| 2024 | 2024-05-09 | 272,059,071 | 8,999,145 | 1,941,720 | 96.13% | Passed |
| 2023 | 2023-05-31 | 288,241,915 | 22,529,801 | 2,231,511 | 92.09% | Passed |
| 2022 | 2022-05-10 | 96,686,563 | 9,405,184 | 747,707 | 90.5% | Passed |
| 2021 | 2021-05-11 | 101,688,287 | 23,676,742 | 1,577,408 | 80.11% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-20 | 94.64%a |
| 2025 | 2025-05-21 | 91.43%b |
| 2024 | 2024-05-09 | 96.13%c |
a. Approved under the standard stated in the filing — “Abstentions are considered voting power present and therefore will have the same effect as a vote against Proposals 2, 3 and 4.”.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote against this proposal, and broker non-votes will have no effect on the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $11,008,126 |
| Median employee compensation | $314,826 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Timothy Williams | EVP and Chief Legal Officer | 2026-04-13 | A | 2,500,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Dawn Carter Bir | Director | 2026-05-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John F. McDonald | Director | 2026-05-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan M. Molineaux | Director | 2026-05-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth G. O'Farrell | Director | 2026-05-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Spiegel | Director | 2026-05-20 | A | 220,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Spiegel | Director | 2026-06-30 | A | 6,103 | 1 | 7,812 | Common | Form 4 ↗ |
| Robert J. Spiegel | Director | 2026-09-30 | A | 6,351 | 1 | 7,812 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (55 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Harout Semerjian. DEF 14A, filed 2026-04-07. Section “Summary Compensation Table”. As printed: 10,221,755. View filing ↗
- Section 01, John Scarlett. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 7,422,754. View filing ↗
- Section 01, Andrew Grethlein. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 3,316,444. View filing ↗
- Section 01, Ahmed ElNawawi. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 2,881,334. View filing ↗
- Section 01, James Ziegler. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 2,392,709. View filing ↗
- Section 01, Michelle Robertson. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 2,250,082. View filing ↗
- Section 01, Joseph Eid. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 1,001,052. View filing ↗
- Section 01, Dawn Bir. DEF 14A, filed 2026-04-07. Section “Executive Compensation Tables and Related Narrative Disclosure” · page 72. As printed: 522,122. View filing ↗
- Section 03, John Scarlett RSU. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Harout Semerjian OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Grethlein RSU. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, James Ziegler RSU. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michelle Robertson RSU. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Ahmed ElNawawi OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Grethlein OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Dawn Bir OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, James Ziegler OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Grethlein OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michelle Robertson OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Scarlett OPTION. DEF 14A, filed 2026-04-07. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-07. Section “CEO Pay Ratio”. As printed: 35 : 1. View filing ↗
- Section 08, Elizabeth G. O'Farrell. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 282,410. View filing ↗
- Section 08, Susan M. Molineaux. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 233,674. View filing ↗
- Section 08, V. Bryan Lawlis. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 233,232. View filing ↗
- Section 08, John F. McDonald. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 231,799. View filing ↗
- Section 08, Robert J. Spiegel. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 226,174. View filing ↗
- Section 08, Gaurav Aggarwal. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 219,612. View filing ↗
- Section 08, Dawn C. Bir. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Patricia S. Andrews. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Harout Semerjian. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Constantine Chinoporos. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, John A. Scarlett. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Timothy Williams 2026-04-13. Form 4, filed 2026-04-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Carter Bir 2026-05-20. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John F. McDonald 2026-05-20. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan M. Molineaux 2026-05-20. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth G. O'Farrell 2026-05-20. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert J. Spiegel 2026-05-20. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert J. Spiegel 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert J. Spiegel 2026-09-30. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-27. Item 5.07 · say-on-pay result. As reported: 94.64% (votes for as printed: 372,129,132). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-27. Item 5.07 · say-on-pay result. As reported: 91.43% (votes for as printed: 361,788,628). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-13. Item 5.07 · say-on-pay result. As reported: 96.13% (votes for as printed: 272,059,071). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 444,857 + equity 0 + all other 0 = 444,857, summed across the director compensation table rows.
- Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
- Axsome Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. View filing ↗
- Geron Corp (subject), Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corp's own proxy. As printed: 10,221,755. View filing ↗
- Revance Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-03-21. CEO total compensation as printed in Revance Therapeutics, Inc.'s own proxy. As printed: 10,068,915. View filing ↗
- Dynavax Technologies, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. View filing ↗
- Syndax Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. View filing ↗
- Coherus Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus Oncology, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- Seres Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Seres Therapeutics, Inc.'s own proxy. As printed: 1,775,549. View filing ↗
- Section 10a, Syndax Pharmaceuticals reciprocity. DEF 14A. Syndax Pharmaceuticals names Geron Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗